Macrolide antibiotics protects against ischemia-reperfusion injury after liver transplantation in rats

doi:10.3969/j.issn.2095-4344.2732

Abstract

Abstract:

BACKGROUND: Liver transplantation is the standard treatment for end-stage liver disease and liver failure. However, ischemia-reperfusion injury can reduce the success rate of liver transplantation. When a limited number of liver donors are available for transplantation, how to reduce liver ischemia-reperfusion injury has become the primary issue in liver transplantation.

OBJECTIVE: To evaluate the effect of macrolide antibiotics on ischemia-reperfusion injury after liver transplantation in rats.

METHODS: Rat autologous orthotopic liver transplantation model was constructed. Wistar rats were randomly divided into macrolide antibiotics group and control group. In the macrolide antibiotics group, the donor liver was treated with macrolide antibiotics (60 mg/kg roxithromycin, 20 mg/kg clarithromycin and 40 mg/kg erythromycin) 30 minutes before hepatectomy, and the above macrolide antibiotic mixture was injected into the portal vein immediately after orthotopic liver transplantation. In the control group, rats were pretreated with the same volume of saline for 30 minutes before hepatectomy, and the same volume of saline was injected into the portal vein immediately after orthotopic liver transplantation. The survival rate of the rats was observed within 7 days after liver transplantation. The serum aspartate aminotransferase and alanine aminotransferase activities were detected by automatic biochemical analyzer at 48 and 72 hours after liver transplantation. Hematoxylin-eosin staining and immunohistochemistry assay were used to detect the morphological changes of liver tissues and the number of Ki-67 positive cells in liver transplantation rats. TUNEL and western blot assay were used to detect the number of apoptotic hepatocytes and the expression of caspase-3 and cleaved caspase-3 proteins in liver transplantation rats, respectively. The Kupffer cell number changes and levels of interleukin-6, interleukin-1β, and tumor necrosis factor-α in rat liver tissues after liver transplantation were detected by immunofluorescence and ELISA, respectively.

RESULTS AND CONCLUSION: Macrolide antibiotics increased the overall survival rate of liver transplanted rats, improved the dysfunction of transplanted liver, reduced the severity of ischemia-reperfusion injury after liver transplantation, increased the regenerative capacity of transplanted liver, reduced the number of apoptotic cells and the ratio of cleaved caspase-3/caspase-3 in the transplanted liver tissue, and decreased the number of Kupffer cells and the levels of interleukin-6, interleukin-1β and tumor necrosis factor-α in the transplanted liver. All the results indicate that macrolide antibiotics protect against ischemia-reperfusion injury in rats undergoing liver transplantation.

Key words: macrolide antibiotics, orthotopic liver transplantation, ischemia-reperfusion injury, liver regeneration, liver function, protection

CLC Number:

Yang Feng, Chang Lipu, Huang Changshan, Gong Xiaoguang, Chang Shunwu. Macrolide antibiotics protects against ischemia-reperfusion injury after liver transplantation in rats[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(26): 4176-4182.

Figures/Tables 5

References

[1] THORSEN T, SOLHEIM JM, LABORI KJ, et al. Liver transplantation as a lifesaving procedure for posthepatectomy liver failure and iatrogenic liver injuries.Langenbecks Arch Surg.2019;404(3):301-308.

[2] SHI S, VERSTEGEN MMA, MEZZANOTTE L, et al. Necroptotic cell death in liver transplantation and underlying diseases: mechanisms and clinical perspective. Liver Transpl. 2019;25(7):1091-1104.

[3] TEOH NC. Hepatic ischemia reperfusion injury: contemporary perspectives on pathogenic mechanisms and basis for hepatoprotection-the good, bad and deadly. J Gastroenterol Hepatol.2011; 26 Suppl 1:180-187.

[4] BHOGAL RH, WESTON CJ, VELDUIS S, et al. The reactive oxygen species-mitophagy signaling pathway regulates liver endothelial cell survival during ischemia/reperfusion injury. Liver Transpl.2018; 24(10):1437-1452.

[5] VAN GOLEN RF, REINIERS MJ, OLTHOF PB, et al. Sterile inflammation in hepatic ischemia/reperfusion injury: present concepts and potential therapeutics. J Gastroenterol Hepatol. 2013;28(3):394-400.

[6] KUYVENHOVEN JP, MOLENAAR IQ, VERSPAGET HW, et al. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury. Thromb Haemost.2004;91(3):506-513.

[7] BUSUTTIL RW, TANAKA K. The utility of marginal donors in liver transplantation. Liver Transpl.2003;9:651-663.

[8] 陈峰,王建,张雅敏.FK506抑制HMGB1的释放减轻肝移植大鼠肝脏缺血再灌注损伤[J].世界华人消化杂志, 2017,25(4): 326-333.

[9] CANNISTRÀ M, RUGGIERO M, ZULLO A, et al. Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers. Int J Surg.2016; 33 Suppl 1:S57-S70.

[10] DE VRIES Y, BERENDSEN TA, FUJIYOSHI M, et al. Transplantation of high-risk donor livers after resuscitation and viability assessment using a combined protocol of oxygenated hypothermic, rewarming and normothermic machine perfusion: study protocol for a prospective, single-arm study (DHOPE-COR-NMP trial). BMJ Open.2019; 9(8):e028596.

[11] LIN SD, LEE KRISHNAMOORTHY T, KUMAR R, et al. Tacrolimus monotherapy in recipients of liver transplant: A single-center experience. Transplant Proc.2019;51(6): 1920-1922.

[12] HUBER R, KASISCHKE K, LUDOLPH AC, et al. Increase of cellular hypoxic tolerance by erythromycin and other antibiotics. NeuroReport.1999;10(7):1543-1546.

[13] KOUTSOGIANNIDIS C-PC, JOHNSON EO. Pharmacological neuroprotection in cardiac surgery: effectiveness of pharmacologic-preconditioning with erythromycin. Curr Vasc Pharmacol.2018; 16(4):329-335.

[14] TROTTER JF, LIZARDO-SANCHEZ L. Everolimus in liver transplantation. Curr Opin Organ Transplant. 2014;19(6): 578-582.

[15] NARUMI S, WATARAI Y, GOTO N, et al. Everolimus-based immunosuppression possibly suppresses mean fluorescence intensity values of de novo donor-specific antibodies after primary kidney transplantation. Transplant Proc.2019; 51(5): 1378-1381.

[16] CZIGANY Z, SCHERER MN, PRATSCHKE J, et al. Technical aspects of orthotopic liver transplantation-a survey-based study within the eurotransplant, swisstransplant, scandiatransplant, and british transplantation society networks. J Gastrointest Surg.2019;23(3):529-537.

[17] CZIGÁNY Z, IWASAKI J, YAGI S, et al. Improving research practice in rat orthotopic and partial orthotopic liver transplantation: a review, recommendation, and publication guide. Eur Surg Res.2015; 55(1-2):119-138.

[18] SCAFFIDI P, MISTELI T, BIANCHI ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191-195.

[19] 常琦,王琴.吡格列酮对肝脏缺血再灌注损伤模型大鼠的保护作用[J].解放军药学学报,2018,34(5):401-404.

[20] THOMSEN KL, ROBERTSON FP, HOLLAND-FISCHER P, et al. The macrophage activation marker soluble CD163 is associated with early allograft dysfunction after liver transplantation. J Clin Exp Hepatol. 2019;9(3):302-311.

[21] ELTZSCHIG HK, ECKLE T. Ischemia and reperfusion--from mechanism to translation. Nat Med. 2011;17(11):1391-1401.

[22] MENDES-BRAZ M, ELIAS-MIRÓ M, JIMÉNEZ-CASTRO MB, et al. The current state of knowledge of hepatic ischemia-reperfusion injury based on its study in experimental models. J Biomed Biotechnol. 2012;2012:298657.

[23] ABU-AMARA M, YANG SY, TAPURIA N, et al. Liver ischemia/reperfusion injury: processes in inflammatory networks--a review. Liver Transpl.2010;16(9):1016-1032.

[24] GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther.2019; 49(10):1260-1273.

[25] LI Z, ZHANG J, MULHOLLAND M, et al. mTOR activation protects liver from ischemia/reperfusion-induced injury through NF-κB pathway. FASEB J.2017;31(7):3018-3026.

[26] LI Z, GU J, ZHU Q, LIU J, et al. Obese donor mice splenocytes aggravated the pathogenesis of acute graft-versus-host disease via regulating differentiation of Tregs and CD4+ T cell induced-type I inflammation. Oncotarget.2017;8(43):74880-74896.

[27] WU Y, WANG W, PENG XM, et al. Rapamycin upregulates connective tissue growth factor expression in hepatic progenitor cells through TGF-β-Smad2 dependent signaling. Front Pharmacol.2018;9:877.

[28] LIM EJ, CHIN R, NACHBUR U, et al. Effect of immunosuppressive agents on hepatocyte apoptosis post-liver transplantation. PLoS One.2015;10(9):e0138522.

[29] CHAUDHRY S, EMOND J, GRIESEMER A. Immune cell trafficking to the liver. Transplantation. 2019;103(7): 1323-1337.

[30] BAI H, WEN J, GONG JP, et al. Blockade of the Notch1/ Jagged1 pathway in Kupffer cells aggravates ischemia-reperfusion injury of orthotopic liver transplantation in mice. Autoimmunity.2019;52(4):176-184.

[31] AL-SAEEDI M, LIANG R, SCHULTZE DP, et al. Glycine protects partial liver grafts from Kupffer cell-dependent ischemia-reperfusion injury without negative effect on regeneration. Amino Acids.2019; 51(6):903-911.

[32] TAMURA T, KONDO T, PAK S, et al. Interaction between Kupffer cells and platelets in the early period of hepatic ischemia-reperfusion injury--an in vivo study. J Surg Res. 2012;178(1):443-451.

[33] YUAN DD, CHI XJ, JIN Y, et al. Intestinal injury following liver transplantation was mediated by TLR4/NF-κB activation-induced cell apoptosis. Mol Med Rep.2016;13(2): 1525-1532.